Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous system.
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous system.
复制标题
钆磷维三钠对比增强磁共振静脉造影:颅内和颅外静脉系统的评估。
DOI:
10.1002/jmri.24409
复制
发表时间:
2014
期刊:
影响因子:
--
通讯作者:
Wolinsky,JerryS
中科院分区:
文献类型:
--
作者:
Kramer,LarryA;Cohen,AlanM;Hasan,KhaderM;Heimbigner,JaredH;Barreto,AndrewD;Brod,StaleyA;Narayana,PonnadaA;Wolinsky,JerryS
PurposeTo demonstrate the efficacy of contrast enhanced magnetic resonance venography (CEMRV) using gadofosveset trisodium in the comprehensive evaluation of the intracranial and extracranial venous system.Materials and MethodsTemporal signal decay, in‐plane saturation and flow artifacts were assessed in an institutional review board approved, HIPAA compliant CEMRV study of 99 subjects. In a 39 subject subset, percent diameter narrowing of the internal jugular (IJ), brachiocephalic and azygous veins were coded according to the following ordinal grades for both catheter venography (CV) and CEMRV: grade 0 ≤ 50%, grade 1 >50% and ≤ 75%, grade 2 >75% and <100% and grade 3 = 100% and compared with pressure gradient measurements obtained during CV.ResultsThere was no significant signal decay, in‐plane saturation or flow artifacts identified on CEMRV or hemodynamically significant pressure gradients identified on CV. All brachiocephalic and azygous veins had matched grade 0 narrowing on both modalities. Discrepancy between modalities occurred in the IJ veins at the level of thyroid gland where 15% of IJ veins had CEMRV grade ≥ 1 narrowing compared with 4% for CV or below the thyroid gland where 5% of IJ veins had CEMRV grade ≥ 1 narrowing compared with 20% for CV. There was fair agreement (κ = 0.24) between modalities for grade of narrowing in the combined data set of all coded veins.ConclusionCEMRV using gadofosveset trisodium is accurate in the evaluation of the venous system.J. Magn. Reson. Imaging 2014;40:630–640. ©2013 Wiley Periodicals, Inc.